Skip to main content
OpenTrials

Clinical trial condition

Locally Advanced Urothelial Carcinoma

Explore clinical trials studying Locally Advanced Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

18 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Locally Advanced Urothelial Carcinoma trial results

Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

NCT06524544

Conditions
Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Urothelial Carcinoma, +5 more
Locations
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 159 locations
View Trial Details
Active, Not Recruiting

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

NCT03244384

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Localized Renal Pelvis and Ureter Urothelial Carcinoma, +19 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 915 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

NCT03854474

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +16 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut, United States
View all 34 locations
View Trial Details
Active, Not Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details

Related conditions